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Abstract Periprosthetic fractures after massive endo-
prosthetic reconstructions pose a reconstructive challenge
and jeopardize limb preservation. Compressive osseointe-
gration technology offers the promise of relative ease of
prosthetic revision, since ﬁxation is achieved by means of a
short intramedullary device. We retrospectively reviewed
the charts of 221 patients who had Compress
1 devices
implanted in two centers between December, 1996 and
December, 2008. The mean followup was 50 months
(range, 1–123 months). Six patients (2.7%) sustained
periprosthetic fractures and eight (3.6%) had nonperipros-
thetic ipsilateral limb fractures occurring from 4 to
79 months postoperatively. All periprosthetic fractures
occurred in patients with distal femoral implants (6/154,
3.9%). Surgery was performed in all six patients with
periprosthetic femur fractures and for one with a nonperi-
prosthetic patellar fracture. The osseointegrated interface
was radiographically stable in all 14 cases. All six patients
with periprosthetic fracture underwent limb salvage pro-
cedures. Five patients had prosthetic revision; one patient
who had internal ﬁxation of the fracture ultimately under-
went amputation for persistent infection. Periprosthetic
fractures involving Compress
1 ﬁxation occur infrequently
and most can be treated successfully with further surgery.
When implant revision is needed, the bone preserved by
virtue of using a shorter intramedullary Compress
1 device
as compared to conventional stems, allows for less com-
plex surgery, making limb preservation more likely.
Level of Evidence: Level IV, therapeutic study. See
Guidelines for Authors for a complete description of levels
of evidence.
Introduction
Given the increasing number of primary and revision
arthroplasty cases performed, the prevalence of unce-
mented devices, the improvements in implant survivorship,
and an active but aging patient population with attendant
comorbidities such as osteoporosis, periprosthetic fractures
are an increasingly common complication [4]. The inci-
dence of periprosthetic femoral fractures around total hip
and knee replacements has been estimated at 4.1% and
2.8%, respectively [3, 16, 17, 38]. A recent review con-
cluded, however, ‘‘There is little information about the
overall incidence (the risk) of periprosthetic fracture in a
broader perspective, taking, for example, time since oper-
ation into account’’ [24]. Furthermore, treatment
algorithms are often quite complex [26], and little has been
published regarding treatment outcomes.
Comparatively less is known about the incidence and
results of periprosthetic fractures around massive endo-
prosthetic implants typically used for limb salvage
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femoral and proximal tibial periprosthetic fracture rates of
0.9% and 2%, respectively [20], the literature provides
little guidance regarding management and expected out-
come of such fractures. For conventional cemented and
uncemented devices, revision is complicated by excessive
stem length and consequent sacriﬁce of bone stock in
patients who frequently have high activity demands and a
long life expectancy.
Compressive osseointegration technology was devised
to provide stable ﬁxation of endoprostheses by way of a
novel spring-loaded system anchored by a short intra-
medullary device [2, 5, 9, 11, 23, 30]. Some concern
existed that the Compress
1 implant would potentially be
subject to an increased risk of periprosthetic fracture par-
ticularly at the transverse pin placement sites. Furthermore,
it was thought that any torque load sufﬁcient to cause a
periprosthetic fracture would also result in disruption of the
bone-prosthetic interface. Initial prosthetic survivorship
results nonetheless have been encouraging when distal
femoral Compress
1 implants were compared with con-
ventional cemented stems [5]. As our experience with the
Compress
1 device has developed, we have noted that the
design allows for relatively straightforward revision in
cases of infection or periprosthetic fracture [30].
Our purposes were to determine: (1) the frequency of
ipsilateral limb fractures associated with Compress
1
implants; (2) whether they were periprosthetic or non-
periprosthetic; (3) time to fracture; (4) how they were
treated; and (5) the effect of these fractures on prosthetic
retention, maintenance of limb salvage, and ambulatory
status.
Materials and Methods
Weretrospectivelyreviewedtherecordsof221patientswho
hadCompress
1devicesimplantedbetweenDecember 1996
and December 2008 for patients with the following indica-
tions: primary oncology (165); revision oncology (33);
revision arthroplasty (18); and post-traumatic reconstruc-
tion (ﬁve). The anatomic locations were as follows: distal
femoral (154), proximal tibial (38), proximal femoral (23),
distal humeral (four), and proximal humeral (two). All
ipsilateral limb fractures were recorded, and classiﬁed as
periprosthetic or nonperiprosthetic (deﬁned as fractures not
adjacent to the Compress
1 implant). The minimum fol-
lowupforpatientswithperiprostheticfracturesafterfracture
treatmentwas14 months(median,62 months;range,14–94
months) and the minimum followup for nonperiprosthetic
fractures was 4 months (median, 24 months; range, 4–89
months). No patients were lost to followup. We obtained
prior Institutional Review Board approval.
Previously published methods of Compress
1 surgery
were followed [30]. For any given primary or revision
indication, an osteotomy through bone of normal quality
was made perpendicular to the longitudinal axis of the
bone. Triple reamers were utilized to ensure the diameter
of the centering sleeve of the device was at least 2 mm
larger than that of the anchor plug. Transverse pins
measuring 4 mm longer than the bone diameter were
implanted through bone of normal quality. Hydroxyapa-
tite-coated spindles of short length and large diameter
with 800 lbs. of force are now frequently chosen for the
femur, while short, small, 600 lb. hydroxyapatite-coated
spindles are selected for tibial cases; anti-rotation pins
are generally not utilized. Care was taken to achieve a
tight ﬁt between the centering sleeve and the endosteal
surface.
To minimize the risk of periprosthetic fracture or spindle
failure through application of rotational torques, patients
with femoral and tibial reconstructions were maintained at
a strictly nonweightbearing gait protocol for six and twelve
weeks, respectively. Thereafter, partial weightbearing was
advanced 25% per week. Gentle active and active-assisted
range of motion and strengthening (quadriceps sets and
straight leg raising) exercises were begun immediately
after surgery. Calcium and vitamin D were also routinely
prescribed. Recreational pursuits more vigorous than hik-
ing, bicycling, and swimming are strongly discouraged;
high or repetitive impact activities and contact sports are
not allowed [30].
Plain radiographs were obtained before discharge from
the hospital, as well as at 2 and 6 weeks after surgery.
Clinical and radiographic examinations were generally
performed at 3-month intervals for the ﬁrst 2 years after
surgery, and at 6-month intervals thereafter. From the
medical records we obtained the following demographic
data: gender, age, surgical indications (primary or revision;
tumor, arthroplasty, or trauma), and whether chemotherapy
or radiation therapy was administered. Radiographs were
examined to identify technical errors, evidence of implant
breakage, or disruption of the bone-prosthetic interface.
From the charts we recorded time to fracture, mechanism
of fracture, fracture management, and outcome with
respect to prosthetic retention, limb preservation, and
ambulatory status.
Results
Fourteen of the 221 patients (6.3%) had ipsilateral limb
fractures. Six of these (2.7%) were periprosthetic and eight
(3.6%) were nonperiprosthetic.
Among those with periprosthetic fractures, there were
two male and four female patients with a median age of
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12324.5 years (range, 13-32 years). Five patients underwent
Compress
1 reconstructions for tumors; one cancer patient
underwent revision of a failed conventional stemmed
device. Three patients received chemotherapy after Com-
press
1 surgery; none received radiation. Median time to
fracture was 6 months (range, 2–20 months). All peri-
prosthetic fractures occurred in association with distal
femoral implants (6/154, 3.9%). Surgery was necessitated
in all patients with periprosthetic fractures. Although
revision was necessitated in one patient who sustained a
fracture at the site of anti-rotation pin insertion (Fig. 1),
four revisions were undertaken for the more common
fracture pattern that occurred above the anchor plug
(Fig. 2). One patient underwent open reduction and inter-
nal ﬁxation (ORIF) (Fig. 3). The osseointegration site was
intact in all cases. There were no instances of implant
fracture. At last followup ﬁve patients retained their pros-
theses without further surgery and were walking without an
assistive device; one patient ultimately underwent ampu-
tation for persistent infection (Table 1).
Among those with minor ipsilateral nonperiprosthetic
fractures, there were ﬁve male and three female patients
with a median age of 14 years (range, 10-29 years). Seven
patients underwent Compress
1 reconstructions for tumors;
one cancer patient underwent revision of a failed Com-
press
1 device. Except for this patient, all patients received
chemotherapy after Compress
1 surgery; one received
adjuvant radiation. Median time to fracture was 8.5 months
(range, 4–79 months). Minor fractures occurred in ﬁve
distal femoral (5/154, 3.2%) and three proximal tibial (3/
38, 7.9%) cases. Fractures in this group included distal
tibial (four), patellar (two), proximal tibial (one), and
proximal ﬁbular (one) locations. Median time to fracture
was 7 months (range, 4–79 months). Only one patient,
with a patellar fracture, required open reduction and
internal ﬁxation (Fig. 4). The remaining patients were
treated nonoperatively. At last followup all prostheses were
retained, and patients were able to walk without the need
for assistive device. Despite forces sufﬁcient to cause
fracture, there were no cases of device breakage, and the
Fig. 1A–B (A) Preoperative and (B) postrevision radiographs of a
32 year-old man who sustained a periprosthetic fracture within two
months after surgery while bearing full weight, contrary to instruc-
tions. (A) The cortical bone splintered where anti-rotation pins had
been inserted into the cortex, just above the osseointegration site;
intraoperative ﬁndings noted that the compression force had not been
lost. (B) Revised implant after resection of an additional 4 cm of
bone.
Fig. 2A–B (A) Preoperative anteroposterior and (B) 5.9 year post-
operative lateral radiographs show a 17-year-old woman with a
history of distal femoral osteosarcoma who sustained a displaced
periprosthetic femoral shaft fracture 1.7 years after treatment with
chemotherapy and Compress
1 reconstruction. (A) Despite the
fracture, the osseointegrated interface remained intact. (B) Revision
was accomplished in a straightforward manner by resection of a
minimal amount of bone and reimplantation of a Compress
1 device.
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all cases (Table 2).
Discussion
We undertook this review to better understand the fre-
quency, location, timing, and management of ipsilateral
limb fractures associated with compressive osseointegra-
tion reconstructions. The effect of such fractures on
prosthetic retention, limb preservation, and ambulatory
status was also studied.
Limitations of this study include its size, length of fol-
lowup, and focus on one type of endoprosthesis. The
limited size and followup make it difﬁcult to draw deﬁni-
tive conclusions regarding the time frame for fractures to
occur. Experience with the Compress
1 device reported
here is not directly applicable to periprosthetic fractures in
arthroplasty patients, or even in the majority of tumor
patients, who continue to receive conventional stemmed
implants. Generalization of these results to centers less
experienced in the use of compressive osseointegration
techniques may not be immediately possible. Furthermore,
the study population described here consists largely of
young tumor patients, whereas the Compress
1 device is
being increasingly used for revision arthroplasty patients,
for whom advanced age and osteoporosis may well signal a
higher periprosthetic fracture risk. Another limitation is the
lack of ﬁrm data regarding risk analysis of periprosthetic
fracture per patient-year [24]. However, the paper reports
an experience of more than 200 patients treated over a 12-
year period by four surgeons at two major sarcoma centers.
In addition, the data would seem to conﬁrm the acceptable
risk proﬁle of compressive osseointegration technology for
endoprosthetic ﬁxation with respect to the speciﬁc issues of
periprosthetic fracture incidence, management, and pros-
thetic retention.
The most robust data regarding periprosthetic fractures
from the arthroplasty literature deal with femoral fractures
after total hip replacement, for which the 10-year proba-
bility of fracture has been estimated to be 0.64% [24]. The
annual incidence is thought to vary between 0.045% and
0.13%, with a tendency for the incidence to increase over
time [24]. Treatment is often complex [26], and the
Fig. 3A–B (A) Preoperative and (B) postoperative anteroposterior
radiographs of a 16 year-old woman with a periprosthetic femoral
fracture occurring at an area of cortical thinning where an uncemented
stem had previously been present. (A) The Compress
1 prosthetic-
bone interface is stable. (B) Open reduction and internal ﬁxation was
undertaken without the need for prosthetic revision.
Table 1. Compress
1 periprosthetic fractures
Gender Age at
fracture
Indication Compress
1
location
Adjuvant
chemotherapy?
Adjuvant
radiation?
Fracture
location
Mechanism
of fracture
Time to
fracture
(years)
Treatment Followup
after fracture
(years)
F 17 Primary
oncology
Distal femur Yes No Proximal
femur
Fall on wet
rocks
1.66 Revision 5.92
M 32 Primary
oncology
Distal femur No No Proximal
femur
Fall on cement 0.17 Revision 5.55
F 30 Primary
oncology
Distal femur Yes No Proximal
femur
Fall from step 0.58 Revision 4.8
F 13 Primary
oncology
Distal femur Yes No Proximal
femur
Fall from bus
step
0.91 Revision 1.49
M 29 Primary
oncology
Distal femur No No Proximal
femur
Mechanical
fall
0.42 Revision 7.8
F 16 Revision
oncology
Distal femur No No Proximal
femur
Mechanical
fall
0.17 ORIF 1.2
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123seriousness of this complication is highlighted by the
1-year mortality rate for such patients, which in one study
was 12% for those undergoing revision arthroplasty and
33% for those undergoing ORIF [6].
Comparable information regarding incidence, treatment,
and outcomes for patients with periprosthetic fractures
after megaprosthetic reconstructions, most often performed
for tumors, is lacking. Most large series of intermediate to
long-term results of endoprosthetic implants highlight
implant survivorship, but failure due to periprosthetic
fracture is often not speciﬁcally commented upon [7, 8,
12–15, 18, 21, 25, 32, 33, 36, 37]. Although Inglis and
Walker reported a periprosthetic fracture rate of 37.5% of
ﬁxed hinge devices used to revise failed hinged implants
[19], most recent papers commenting on periprosthetic
fracture risk in primary tumor reconstructions using rotat-
ing hinge devices report rates of 0.3% to 6.1% (Table 3)
[1, 10, 20, 22, 27–29, 31, 34, 35, 39]. Given the relatively
low frequency of this complication, and the wide variety of
Fig. 4A–B (A) Preoperative and (B) 2.4 year postoperative lateral
radiographs of an 18-year-old woman with a history of distal femoral
sarcoma who sustained a displaced patellar fracture 3.8 years after
treatment with chemotherapy, Compress
1 reconstruction, and radi-
ation therapy are shown. (A) Despite a fall from a trampoline, the
bone-prosthetic interfaced remained stable. (B) Healed fracture
despite prior radiation is shown.
Table 2. Compress
1 ipsilateral limb nonperiprosthetic fractures
Gender Age at
fracture
Indication Compress
1
location
Adjuvant
chemotherapy?
Adjuvant
radiation?
Fracture
location
Mechanism
of fracture
Time to
fracture
(years)
Treatment Followup after
fracture (years)
M 14 Primary
oncology
Proximal tibia Yes No Distal tibia Fall from
crutches
0.58 Cast 3.17
M 14 Primary
oncology
Proximal tibia Yes No Distal tibia Fall from
bicycle
1.92 Cast 7.42
M 12 Primary
oncology
Distal femur Yes No Distal tibia Fall off of
bed
0.67 Cast 1.67
F 10 Primary
oncology
Distal femur Yes No Distal tibia Twisting
injury
0.58 Cast 0.67
F 18 Primary
oncology
Distal femur Yes Yes Patella Fall from
trampoline
3.75 ORIF 2.42
F 25 Primary
oncology
Distal femur Yes No Patella Fall at party 6.58 Cast 1.08
M 29 Revision
oncology
Proximal tibia No No Proximal
ﬁbula
Fall on ice 0.33 Brace 2.92
M 10 Primary
oncology
Distal femur Yes No Proximal
tibia
Fall on wet
ﬂoor
0.75 Cast 0.33
Table 3. Studies of periprosthetic fractures associated with
endoprostheses
Study Periprosthetic fractures (%)
Ahlmann et al. [1] 1/211 (0.5)
Capanna et al. [10] 3/95 (3.2)
Jeys et al. [20] 6/661 (0.9)
Kawai et al. [22] 5/82 (6.1)
Mittermayer et al. [27] 2/100 (2)
Mittermayer et al. [28] 4/251 (1.6)
Morgan et al. [29] 1/105 (1)
Orlic et al. [31] 2/90 (2.2)
Torbert et al. [34] 1/139 (0.7)
Unwin et al. [35] 3/1001 (0.3)
Zeegen et al. [39] 2/141 (1.4)
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123implants reported upon, little has been described regarding
optimal surgical management or treatment results of these
fractures.
As compared to historical data regarding arthroplasty
patients as well as cancer patients having conventional
cemented and uncemented stems, we believe the Com-
press
1 device provides acceptable results in terms of the
incidence of periprosthetic fractures in a generally young
tumor population which is nonetheless subject to risk fac-
tors of osteoporosis (secondary to preoperative disuse and
the effects of chemotherapy and radiation) and high
activity demands. When a fracture does occur, Compress
1
technology offers the distinct advantage of comparatively
straightforward revision, given the ease of extraction of the
intramedullary portion of the device, and the minimal
amount of bone (as little as 2 to 4 cm) that needs to be
resected before implantation of a new device. Furthermore,
short metaphyseal-epiphyseal fragments (43 mm or longer)
remaining after fracture can still be salvaged with a short
anchor plug, thus obviating the need for conversion to a
total femoral replacement [30]. Although femoral fractures
above the anchor plug can be expected to occur at any time
in the patient’s life if sufﬁcient force is applied, our ﬁnding
that all periprosthetic fractures occurred within 2 years of
surgery is of potential importance for predicting the risk of
this complication, since the opposite is expected to be true
for typical arthroplasties and megaprostheses [24]. This
difference can be attributed to the cortical hypertrophy
engendered by compressive osseointegration forces; as
demonstrated by Avedian et al. [2], the Compress
1 device
provides, stability and bone growth at the prosthetic
interface over the ﬁrst 6 to 12 months, effectively sealing
the endosteal canal to particulate debris [23, 30]. By con-
trast, stress shielding and osteolysis are expected to be
ever-increasing problems for many tumor megaprosthetic
stems, thereby increasing the risk for aseptic loosening and
periprosthetic fracture with time. Finally, we observed no
instances of mechanical breakage of the Compress
1
device, a ﬁnding that should be considered when compar-
ing conventional endoprosthetic devices, for which implant
fracture has been reported to be as high as 10% [14].
Although case-matched cohort studies are of some utility in
comparing compressive osseointegration technology to
standard stem ﬁxation [5], long term prospective studies
are desirable in order to elucidate this and other compli-
cations before any particular reconstructive approach can
be deﬁnitively endorsed.
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